Challenges in pulmonary fibrosis: 7 · Novel therapies and lung transplantation

Thorax

Volumn 63, Issue 3, 2008, Pages 277-284

  Williams, T J ^a   Wilson, J W ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DECORIN; ETANERCEPT; GAMMA1B INTERFERON; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MACROLIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIRFENIDONE; PREDNISOLONE; PREDNISONE; PROSTAGLANDIN E2; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VALACICLOVIR; VALGANCICLOVIR; VORICONAZOLE;

DISEASE COURSE; DONOR; EXERCISE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUNG TRANSPLANTATION; MESENCHYMAL STEM CELL; NONHUMAN; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEIZURE; SURVIVAL; SURVIVAL RATE; TREATMENT INDICATION; TREMOR;

ANTI-INFLAMMATORY AGENTS; CYTOKINES; HUMANS; INTRAOPERATIVE CARE; LUNG TRANSPLANTATION; PATIENT SELECTION; PULMONARY FIBROSIS; TISSUE AND ORGAN PROCUREMENT; WAITING LISTS;

EID: 40649115984     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.031054     Document Type: Review

References (110)

1. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
2. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277- 304.
3. Gauldie J. Proinflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;165:1205-6.
4. Borzone G, Moreno R, Urrea R, et al. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;163:1648-53.
5. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164:1722-7.
6. Kotton DN, Ma BY, Cardoso WV, et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001;128:5181-8.
7. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:8407-11.
8. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-41.
9. Abuljadayel IS. Induction of stem cell-like plasticity in mononuclear cells derived from unmobilised adult human peripheral blood. Curr Med Res Opin 2003;19:355-75.
10. Bousquet J, Jeffery PK, Busse WW, et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-45.
11. Tamai K, Ishikawa H, Mauviel A, et al. Interferon-gamma coordinately upregulates matrix metalloprotease (MMP)-1 and MMP-3, but not tissue inhibitor of metalloproteases (TIMP), expression in cultured keratinocytes. J Invest Dermatol 1995;104:384-90.
12. Gillery P, Fertin C, Nicolas JF, et al. Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett 1992;302:231-4.
13. Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002;27:419-27.
14. Majumdar S, Li D, Ansari T, et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999;14:251-7.
15. Khalil N, Greenberg AH. The role of TGF-beta in pulmonary fibrosis. Ciba Found Symp 1991;157:194-211.
16. Khalil N, O'Connor RN, Flanders KC, et al. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am J Respir Cell Mol Biol 1996;14:131-8.
17. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-71.
18. Roberts AB, Sporn MB. Transforming growth factor-betas. In: Sporn MB, Roberts AB, eds. Handbook of experimental pharmacology. Heidelberg: Springer-Verlag, 1990:419-72.
19. Sporn MB, Roberts AB, Wakefield LM, et al. Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 1987;105:1039-45.
20. Coker RK, Laurent GJ, Shahzeidi S, et al. Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am J Pathol 1997;150:981-91.
21. Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J Biol Chem 1989;264:1860-9.
22. Eickelberg O, Kohler E, Reichenberger F, et al. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta land TGF-beta3. Am J Physiol 1999;276:L814-24.
23. Broekelmann TJ, Limper AH, Colby TV, et al. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991;88:6642- 6.
24. Venkatesan N, Pini L, Ludwig MS. Changes in Smad expression and sub-cellular localization in bleomycin induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2004;287:L1342-7.
25. Bonniaud P, Kolb M, Galt T, et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunol 2004;173:2099-108.
26. Crystal RG, Bitterman PB, Mossman B, et al. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2002;166:236-46.
27. Zhao J, Sime PJ, Bringas P Jr, et al. Adenovirus-mediated decorin gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis. Am J Physiol 1999;277:L412-22.
28. Sueoka N, Sueoka E, Miyazaki Y, et al. Molecular pathogenesis of interstitial pneumonitis with TNF-alpha transgenic mice. Cytokine 1998;10:124-31.
29. Vilcek J, Palombella VJ, Henriksen-DeStefano D, et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986;163:632-43.
30. Ortiz LA, Lasky J, Hamilton RF Jr, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998;24:721-43.
31. Kohase M, May LT, Tamm I, et al. A cytokine network in human diploid fibroblasts: interactions of beta-interferons, tumor necrosis factor, platelet-derived growth factor, and interleukin-1. Mol Cell Biol 1987;7:273-80.
32. Scharffetter K, Heckmann M, Hatamochi A, et al. Synergistic effect of tumor necrosis factor-alpha and interferon-gamma on collagen synthesis of human skin fibroblasts in vitro. Exp Cell Res 1989;181:409-19.
33. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest 1995;96:250-9.
34. Piguet PF, Kaufman S, Barazzone C, et al. Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis. Int J Exp Pathol 1997;78:43-8.
35. Cavarra E, Carraro F, Fineschi S, et al. Early response to bleomycin is characterised by different cytokine and cytokine receptor profiles in the lungs of fibrosis-prone and fibrosis-resistant mice. Am J Physiol Lung Cell Mol Physiol 2004;287:L1186-92.
36. Zhang Y, Lee TC, Guillemin B, et al. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 1993;150:4188-96.
37. Pan LH, Ohtani H, Yamauchi K, et al. Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int 1996;46:91-9.
38. Kuroki M, Noguchi Y, Shimono M, et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunol 2003;170:567-74.
39. Fujita M, Shannon JM, Morikawa O, et al. Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Am J Respir Cell Mol Biol 2003;29:669-76.
40. Pfeffer LM, Murphy JS, Tamm I. Interferon effects on the growth and division of human fibroblasts. Exp Cell Res 1979;121:111-20.
41. Cornelissen AM, Von den Hoff JW, Maltha JC, et al. Effects of interferons on proliferation and collagen synthesis of rat palatal wound fibroblasts. Arch Oral Biol 1999;44:541-7.
42. Coker RK, Laurent GJ. Pulmonary fibrosis: cytokines in the balance. Eur Respir J 1998;11:1218-21.
43. Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis [see comments]. N Engl J Med 1999;341:1264-9.
44. Raghu G, Brown KK, Bradford W2, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33.
45. Honore I, Nunes H, Groussard O, et al. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis [see comment]. Am J Respir Crit Care Med 2003;167:953-7.
46. Strieter RM, Starko KM, Enelow RI, et al. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004;170:133-40.
47. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;291:367-73.
48. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289:211-8.
49. Schelegle ES, Mansoor JK, Giri S. Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc Soc Exp Biol Med 1997;216:392-7.
50. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061-9.
51. Pueringer RJ, Schwartz DA, Dayton CS, et al. The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest 1993;103:832-8.
52. Wilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995;95:1861-8.
53. Keerthisingam CB, Jenkins RG, Harrison NK, et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001;158:1411-22.
54. Bonner JC, Rice AB, Moomaw CR, et al. Airway fibrosis in rats induced by vanadium pentoxide. Am J Physiol Lung Cell Mol Physiol 2000;278:L209-16.
55. Salas-Prato M, Assalian A, Mehdi AZ, et al. Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitro. J Glaucoma 1996;5:54-9.
56. Simler NR, Howell DC, Marshall RP, et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2002;19:1124-7.
57. Murphy GJ, Nicholson ML. Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early allograft vasculopathy. J Thorac Cardiovasc Surg 2003;126:2058-64.
58. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-15.
59. Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004;125:2169-74.
60. Derom F, Barbier F, Ringoir S, et al. Ten-month survival after lung homotransplantation in man. J Thorac Cardiovasc Surg 1971;61:835-46.
61. Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med 1986;314:1140-5.
62. Ouwens JP, Groen H, TenVergert EM, et al. Simulated waiting list prioritization for equitable allocation of donor lungs. J Heart Lung Transplant 2002;21:797-803.
63. D'Armini AM, Callegari G, Vitulo P, et al. Risk factors for early death in patients awaiting heart-lung or lung transplantation: experience at a single European center. Transplantation 1998;66:123-7.
64. Trulock EP, Edwards LB, Taylor DO, et al. The Registry of the International Society for Heart and Lung Transplantation: 21st official adult heart transplant report: 2004. J Heart Lung Transplant 2004;23:804-15.
65. Levine SM, Anzueto A, Peters JI, et al. Single lung transplantation in patients with systemic disease. Chest 1994;105:837-41.
66. Rosas V, Conte JV, Yang SC, et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000;5:38-43.
67. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-81.
68. Collard HR, King TE. Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. Am J Med 2001;110:326-8.
69. Kizer JR, Zisman DA, Blumenthal NP, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med 2004;164:551-6.
70. Collins J, Kazerooni EA, Lacomis J, et al. Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings. Radiology 2002;224:131-8.
71. Maurer JR, Frost AE, Estenne M, et al. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 1998;66:951-6.
72. Snell GI, De Hoyos A, Winton T, et al. Lung transplantation in patients over the age of 50. Transplantation 1993;55:562-6.
73. Kanasky WF Jr, Anton SD, Rodrigue JR, et al. Impact of body weight on long-term survival after lung transplantation. Chest 2002;121:401-6.
74. Durieux S, Mercadal L, Orcel P, et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 2002;74:496-500.
75. Patel S, Kwan JT, McCloskey E, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 2001;16:1863-70.
76. Snell GI, Walters EH, Kotsimbos TC, et al. Idiopathic pulmonary fibrosis: in need of focused and systematic management. Med J Aust 2001;174:137-40.
77. Homma A, Anzueto A, Peters JI, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation [see comment]. J Heart Lung Transplant 2001;20:833-9.
78. Snell GI, Richardson M, Griffiths AP, et al. Coronary artery disease in potential lung transplant recipients >50 years old: the role of coronary intervention. Chest 1999;116:874-9.
79. Lee R, Meyers BF, Sundt TM, et al. Concomitant coronary artery revascularization to allow successful lung transplantation in selected patients with coronary artery disease. J Thorac Cardiovasc Surg 2002;124:1250-1.
80. Nathan SD, Barnett SD, Urban BA, et al. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest 2003;123:1758-63.
81. Starnes VA, Barr ML, Schenkel FA, et al. Experience with living-donor lobar transplantation for indications other than cystic fibrosis. J Thorac Cardiovasc Surg 1997;114:917-21.
82. Steen S, Liao Q, Wierup PN, et al. Transplantation of lungs from non-heart-beating donors after functional assessment ex vivo. Ann Thorac Surg 2003;76:244-52.
83. Steen S, Sjoberg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor. Lancet 2001;357:825-9.
84. Sundaresan S, Semenkovich J, Ochoa L, et al. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. J Thorac Cardiovasc Surg 1995;109:1075-80.
85. Gabbay E, Williams TJ, Griffiths AP, et al. Maximizing the utilization of donor organs offered for lung transplantation. Am J Respir Crit Care Med 1999;160:265-71.
86. Bhorade SM, Vigneswaran W, McCabe MA, et al. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000;19:1199-204.
87. Bittner HB, Dunitz J, Hertz M, et al. Hyperacute rejection in single lung transplantation: case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation 2001;71:649-51.
88. Brumble LM, Milstone AP, Loyd JE, et al. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir. Chest 2002;121:407-14.
89. Palmer SM, Grinnan DC, Diane Reams B, et al. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 2004;18:179-85.
90. Snell GI, Rabinov M, Griffiths A, et al. Pulmonary allograft ischemic time: an important predictor of survival after lung transplantation. J Heart Lung Transplant 1996;15:160-8.
91. Ueno T, Snell GI, Williams TJ, et al. Impact of graft ischemic time on outcomes after bilateral sequential single-lung transplantation. Ann Thorac Surg 1999;67:1577-82.
92. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002;21:540-6.
93. Gerhardt SG, McDyer JF, Girgis RE, et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003;168:121-5.
94. Cairn J, Yek T, Banner NR, et al. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003;22:50-7.
95. Verleden GM, Buyse B, Delcroix M, et al. Cyclophosphamide rescue therapy for chronic rejection after lung transplantation. J Heart Lung Transplant 1999;18:1139-42.
96. Diamond DA, Michalski JM, Lynch JP, et al. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. Int J Radiat Oncol Biol Phys 1998;41:795- 800.
97. Dusmet M, Maurer J, Winton T, et al. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 1996;15:948-54.
98. Snell GI, Esmore DS, Williams TJ. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation. Chest 1996;109:874-8.
99. Calvo V, Borro JM, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999;115:1301-4.
100. Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis [see comment]. J Heart Lung Transplant 2002;21:226-32.
101. Trulock EP, Edwards LB, Taylor DO, et al. The Registry of the International Society for Heart and Lung Transplantation: 20th official adult lung and heart-lung transplant report: 2003. J Heart Lung Transplant 2003;22:625-35.
102. Haider Y, Yonan N, Mogulkoc N, et al. Bronchiolitis obliterans syndrome in single lung transplant recipients: patients with emphysema versus patients with idiopathic pulmonary fibrosis. J Heart Lung Transplant 2002;21:327-33.
103. Venirta F, Boehler A, Rendina EA, et al. Complications in the native lung after single lung transplantation. Eur J Cardio-Thorac Surg 1999;16:54-8.
104. Meyers BF, Lynch JP, Trulock EP, et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg 2000;120:99- 107.
105. Ouwens JP, van den Berg JW, van der BW, et al. Long-term survival despite early loss of graft function after single lung transplantation for pulmonary fibrosis. J Heart Lung Transplant 2002;21:395-401.
106. Williams TJ, Snell GI. Early and long-term functional outcomes in unilateral, bilateral, and living-related transplant recipients. Clin Chest Med 1997;18:245-57.
107. Martinez JA, Paradis IL, Dauber JH, et al. Spirometry values in stable lung transplant recipients. Am J Respir Crit Care Med 1997;155:285-90.
108. Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant 1997;16:313-9.
109. Williams TJ, Grossman RF, Maurer JR. Long-term functional follow-up of lung transplant recipients. Clin Chest Med 1990;11:347-58.
110. Stavem K, Bjortuft O, Lund MB, et al. Health-related quality of life in lung transplant candidates and recipients. Respiration 2000;67:159-65.